Exercise on Semaglutide and Tirzepatide: What Houston Physicians Recommend

GLP-1 medications like semaglutide and tirzepatide work largely by suppressing appetite, which creates a significant caloric deficit. In clinical trials, the average patient on semaglutide lost roughly 15% of total body weight over 68 weeks — but studies analyzing body composition found that a meaningful portion of that loss was lean mass (muscle), not just fat. The SURMOUNT-1 trial for tirzepatide showed similar patterns. Without an intentional resistance training stimulus, the body has no metabolic signal to maintain muscle tissue when energy intake drops sharply. Houston obesity medicine physicians consistently report that patients who don't prioritize strength training during GLP-1 treatment finish their program lighter but with a worse body composition ratio than patients who lift weights regularly.

Most Houston GLP-1 programs that include exercise guidance recommend 2–4 sessions of resistance training per week as the foundation, with cardiovascular exercise as a supplement rather than the primary focus. Full-body workouts targeting major muscle groups (squats, deadlifts, rows, presses) are more time-efficient than isolated exercises for patients with limited gym time. Resistance bands and bodyweight exercises count — the stimulus matters more than the equipment. The goal is to perform 8–15 repetitions per set at a challenging weight, reaching close to muscular fatigue. This signals the body to maintain (or even build) muscle while fat is being lost from the caloric deficit the medication creates.

Resistance training alone is not sufficient to preserve muscle mass on a GLP-1 — protein intake is equally important. When appetite is suppressed by semaglutide or tirzepatide, many patients naturally eat significantly less protein alongside fewer calories. Most Houston providers recommend targeting 0.7–1.0 grams of protein per pound of goal body weight per day (roughly 100–160 grams/day for a 160-pound goal weight). High-quality protein sources — eggs, Greek yogurt, cottage cheese, chicken, fish, tofu, and protein shakes — should be prioritized at each meal. Because GLP-1 medications delay gastric emptying, spreading protein intake across 3–4 smaller meals is often more manageable than trying to hit the target in two large meals.

Cardiovascular exercise has clear benefits for heart health, blood pressure, blood sugar regulation, and mood — all relevant for GLP-1 patients. However, it should not come at the expense of resistance training or recovery. Most Houston physicians recommend 150 minutes of moderate cardiovascular activity per week (brisk walking counts) as a complement to strength training, not a replacement for it. In Houston's heat, outdoor cardio timing matters: early morning or evening workouts and climate-controlled facilities avoid the dangerous summer conditions. Many Houston-area gyms offer group fitness classes that combine light resistance work with cardio — these are a reasonable option for patients who find traditional gym workouts daunting.

GLP-1 medications suppress appetite most strongly in the first 24–48 hours after injection. Some patients find they have minimal appetite for food — including pre- or post-workout nutrition — on injection days. If you inject once weekly, consider timing your injection day to fall on a rest day rather than a heavy training day, which allows better pre-workout fueling. If post-workout appetite suppression is making it difficult to hit protein targets, a liquid protein shake (25–40 grams of protein) immediately after training is typically easier to consume than a full meal when you're not hungry.

The core exercise recommendations are the same for both medications — resistance training to preserve muscle, adequate protein intake, and cardio as a supplement. The practical difference is that tirzepatide tends to produce a larger caloric deficit (average 21% body weight loss versus 15% for semaglutide in trials), which makes the muscle-preservation imperative even stronger. Patients on tirzepatide who are not resistance training are at higher risk of losing clinically significant lean mass. Houston providers managing tirzepatide patients often track body composition (DEXA scan or bioelectrical impedance) every 3–6 months to monitor the fat-to-muscle loss ratio — ask your clinic if they offer this.

Fatigue is common in the first 4–8 weeks on semaglutide or tirzepatide, particularly during dose-escalation phases, when nausea and reduced caloric intake can leave you feeling drained. Houston physicians typically advise patients to maintain movement even when intensity isn't possible — 20–30 minute walks count and help with GI side effects, blood sugar regulation, and mood. Once the body adapts to the lower caloric intake (typically by weeks 8–12 for most patients), energy levels usually improve and a more structured resistance training program becomes feasible. Don't force high-intensity workouts during the first month — consistency matters more than intensity at the start.